FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC
FDA Approval: Datopotamab Deruxtecan for EGFR NSCLC by IASLC
-------- Â
45:33
--------
45:33
LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC
LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC by IASLC
-------- Â
46:33
--------
46:33
IASLC_WCLC 2025 Preview
IASLC_WCLC 2025 Preview by IASLC
-------- Â
45:13
--------
45:13
Virtual Tumor Board: Resectable EGFR NSCLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Chunxia Su and Dr. Collin Blakely. The case explores resectable EGFR NSCLC.
-------- Â
39:29
--------
39:29
FDA Approval: Taletrectinib and ROS1 NSCLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer help place this new agent in the proper perspective.
Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda
South Africa